Thus, PDEVs may also act as immune enhancers to alter the tumor microenvironment, affect the expression of IL-8 and VEGF or other immune factors, and improve the sensitivity to immune drugs in the late stage of GU cancer. The gene discussed is CXCL8; the disease is neoplasm.